Vertex Pharmaceuticals VX-548 Phase 2 Results Diabetic Neuropathy 2023

Vertex Pharmaceuticals presents Phase 2 results for VX-548, a selective NaV1.8 inhibitor in development for painful diabetic peripheral neuropathy and other neuropathic pain indications. The candidate targets underlying pain biology and addresses significant unmet need in acute and peripheral neuropathic pain markets, with Phase 3 acute pain results expected in early 2024.